DIVISLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.0
| Stock Code | DIVISLAB | Market Cap | 1,83,247 Cr. | Current Price | 6,905 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 71.2 | Book Value | 578 ₹ | Dividend Yield | 0.44 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,477 ₹ | DMA 200 | 6,294 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.05 % | PAT Qtr | 653 Cr. | PAT Prev Qtr | 696 Cr. |
| RSI | 66.5 | MACD | 162 | Volume | 3,65,552 | Avg Vol 1Wk | 4,48,540 |
| Low price | 5,636 ₹ | High price | 7,078 ₹ | PEG Ratio | -7.74 | Debt to equity | 0.01 |
| 52w Index | 88.0 % | Qtr Profit Var | 9.88 % | EPS | 94.8 ₹ | Industry PE | 30.5 |
📊 Financial Overview: Divi’s Laboratories (DIVISLAB) shows strong fundamentals. ROE is 15.6% and ROCE is 20.6%, reflecting efficient capital usage. Debt-to-equity is very low at 0.01, ensuring financial stability. Dividend yield is modest at 0.44%. Quarterly PAT declined slightly from ₹696 Cr. to ₹653 Cr., showing a -9.88% variation, but overall profitability remains robust.
💹 Valuation Indicators: Current P/E of 71.2 is significantly above the industry average of 30.5, suggesting overvaluation. P/B ratio is ~11.9 (6905/578), which is expensive. PEG ratio is negative (-7.74), signaling weak growth prospects relative to valuation. Intrinsic value appears lower than current price, implying cautious accumulation.
🏢 Business Model & Advantage: Divi’s Laboratories operates in pharmaceuticals, specializing in APIs and intermediates. Its competitive advantage lies in global scale, strong compliance standards, and long-term relationships with multinational pharma companies. The company benefits from export demand and industry leadership, though valuations remain stretched.
📈 Entry Zone: A favorable entry zone lies between ₹6,400–6,600, closer to intrinsic value and support levels. Current price (₹6,905) is above this zone, making staggered accumulation advisable.
🔒 Long-Term Holding Guidance: Divi’s Laboratories is a strong long-term compounder due to its industry leadership, debt-free structure, and global demand. Despite stretched valuations, its business moat supports resilience. Long-term investors can hold confidently, while monitoring earnings and valuation corrections.
Positive
- 🌟 Strong ROCE (20.6%) and ROE (15.6%)
- 🌟 Debt-free balance sheet (0.01 debt-to-equity)
- 🌟 Global scale and strong compliance standards
- 🌟 FII holdings increased (+0.21%)
Limitation
- ⚠️ Very high P/E (71.2) vs industry average (30.5)
- ⚠️ High P/B (~11.9)
- ⚠️ PEG ratio negative (-7.74)
- ⚠️ Dividend yield modest (0.44%)
Company Negative News
- 📉 PAT declined from ₹696 Cr. to ₹653 Cr.
- 📉 DII holdings reduced (-0.05%)
Company Positive News
- 📈 FII holdings increased (+0.21%)
- 📈 Strong industry positioning and export demand
Industry
- 🏦 Industry P/E at 30.5 reflects moderate valuations
- 🏦 Pharma sector supported by global demand for APIs and intermediates
Conclusion
✅ Divi’s Laboratories is financially strong with industry leadership and a debt-free balance sheet, but stretched valuations limit attractiveness. A better entry zone lies between ₹6,400–6,600. Long-term investors can hold confidently, leveraging its global positioning while awaiting valuation corrections.
Would you like me to also prepare a pharma sector outlook to evaluate how global demand and regulatory trends could influence Divi’s Laboratories’ long-term trajectory?